G
The startup develops autologous, adoptive T-cell therapies that enhance the immune system's ability to target and eliminate cancer cells by recognizing previously overlooked tumor-specific antigens. This approach aims to improve patient responsiveness to a broader range of cancer types, addressing the limitations of conventional cancer treatments.
Natick, United States
Updated 2 months ago
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops autologous, adoptive T-cell therapies that enhance the immune system's ability to target and eliminate cancer cells by recognizing previously overlooked tumor-specific antigens. This approach aims to improve patient responsiveness to a broader range of cancer types, addressing the limitations of conventional cancer treatments.